Treatment of slow-channel congenital myasthenic syndrome in a Thai family with fluoxetine

2022 ◽  
Vol 96 ◽  
pp. 85-89
Author(s):  
Charungthai Dejthevaporn ◽  
Suppachok Wetchaphanphesat ◽  
Teeratorn Pulkes ◽  
Sasivimol Rattanasiri ◽  
Andrew G. Engel ◽  
...  
2010 ◽  
Vol 24 (S1) ◽  
Author(s):  
Jose Gabriel Grajales ◽  
Gary Grajales ◽  
Carlos Baez ◽  
Haipeng Zhu ◽  
Oreste Quesada ◽  
...  

Author(s):  
John H. J. Wokke ◽  
Pieter A. van Doorn ◽  
Jessica E. Hoogendijk ◽  
Marianne de Visser

2015 ◽  
Vol 270 ◽  
pp. 88-94 ◽  
Author(s):  
Haipeng Zhu ◽  
Gary E. Grajales-Reyes ◽  
Vivianette Alicea-Vázquez ◽  
Jose G. Grajales-Reyes ◽  
KaReisha Robinson ◽  
...  

2011 ◽  
Vol 21 (3) ◽  
pp. 214-218 ◽  
Author(s):  
Rawiphan Witoonpanich ◽  
Teeratorn Pulkes ◽  
Charungthai Dejthevaporn ◽  
Praphan Yodnopklao ◽  
Pirada Witoonpanich ◽  
...  

2010 ◽  
Vol 20 (9-10) ◽  
pp. 630
Author(s):  
R. Witoonpanich ◽  
T. Pulkes ◽  
C. Dejthevaporn ◽  
P. Yodnopklao ◽  
P. Witoonpanich ◽  
...  

Author(s):  
Alexander K. C. Leung ◽  
Cham Pion Kao ◽  
Andrew L. Wong ◽  
Alexander K. C. Leung ◽  
Thomas Kolter ◽  
...  

2009 ◽  
Vol 133 (2) ◽  
pp. 151-169 ◽  
Author(s):  
Sergio Elenes ◽  
Michael Decker ◽  
Gisela D. Cymes ◽  
Claudio Grosman

The slow-channel congenital myasthenic syndrome (SCCMS) is a disorder of the neuromuscular junction caused by gain-of-function mutations to the muscle nicotinic acetylcholine (ACh) receptor (AChR). Although it is clear that the slower deactivation time course of the ACh-elicited currents plays a central role in the etiology of this disease, it has been suggested that other abnormal properties of these mutant receptors may also be critical in this respect. We characterized the kinetics of a panel of five SCCMS AChRs (αS269I, βV266M, ɛL221F, ɛT264P, and ɛL269F) at the ensemble level in rapidly perfused outside-out patches. We found that, for all of these mutants, the peak-current amplitude decreases along trains of nearly saturating ACh pulses delivered at physiologically relevant frequencies in a manner that is consistent with enhanced entry into desensitization during the prolonged deactivation phase. This suggests that the increasingly reduced availability of activatable AChRs upon repetitive stimulation may well contribute to the fatigability and weakness of skeletal muscle that characterize this disease. Also, these results emphasize the importance of explicitly accounting for entry into desensitization as one of the pathways for burst termination, if meaningful mechanistic insight is to be inferred from the study of the effect of these naturally occurring mutations on channel function. Applying a novel single-channel–based approach to estimate the contribution of Ca2+ to the total cation currents, we also found that none of these mutants affects the Ca2+-conduction properties of the AChR to an extent that seems to be of physiological importance. Our estimate of the Ca2+-carried component of the total (inward) conductance of wild-type and SCCMS AChRs in the presence of 150 mM Na+, 1.8 mM Ca2+, and 1.7 mM Mg2+ on the extracellular side of cell-attached patches turned out be in the 5.0–9.4 pS range, representing a fractional Ca2+ current of ∼14%, on average. Remarkably, these values are nearly identical to those we estimated for the NR1-NR2A N-methyl-d-aspartate receptor (NMDAR), which has generally been considered to be the main neurotransmitter-gated pathway of Ca2+ entry into the cell. Our estimate of the rat NMDAR Ca2+ conductance (using the same single-channel approach as for the AChR but in the nominal absence of extracellular Mg2+) was 7.9 pS, corresponding to a fractional Ca2+ current of 13%.


2000 ◽  
Vol 1 (4) ◽  
pp. 186-190 ◽  
Author(s):  
Richard S. Bedlack ◽  
Tulio E. Bertorini ◽  
Donald B. Sanders

Sign in / Sign up

Export Citation Format

Share Document